Legend Biotech Corporation (NASDAQ:LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that. On April 19th, a data ...
Investor's Business Daily on MSN
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Arcellx stock reversed lower Monday despite positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. Please watch the video at Investors.com - How To Buy Stocks: IBD's ...
Hosted on MSN
What Makes Legend Biotech (LEGN) a New Buy Stock
Legend Biotech Corporation Sponsored ADR (LEGN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most ...
Legend Biotech is poised for upside, driven by Carvykti’s strong sales and potential label expansion into earlier multiple myeloma treatment lines. Recent FDA draft guidance allowing MRD negativity as ...
One stock that might be an intriguing choice for investors right now is Legend Biotech Corporation LEGN. This is because this security in the Medical - Biomedical and Genetics space is seeing solid ...
Shares of Legend Biotech Corp. LEGN gained 3.7% premarket on Thursday after the company said its multiple myeloma therapy Carvykti, a collaboration with Johnson & Johnson JNJ, generated $117 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results